Citigroup Inc Cerus Corp Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Cerus Corp stock. As of the latest transaction made, Citigroup Inc holds 139,918 shares of CERS stock, worth $250,453. This represents 0.0% of its overall portfolio holdings.

Number of Shares

139,918

Previous 40,902 242.08%

Holding current value

$250,453

Previous $71,000 242.25%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.7 - $2.39 $168,327 - $236,648	99,016 Added 242.08%	139,918 $243,000
Q2 2024 Aug 12, 2024	BUY	$1.62 - $2.04 $16,974 - $21,375	10,478 Added 34.44%	40,902 $71,000
Q1 2024 May 10, 2024	BUY	$1.66 - $2.42 $7,310 - $10,657	4,404 Added 16.93%	30,424 $57,000
Q4 2023 Feb 09, 2024	BUY	$1.25 - $2.35 $28,817 - $54,176	23,054 Added 777.28%	26,020 $56,000
Q3 2023 Nov 09, 2023	SELL	$1.5 - $3.07 $81,576 - $166,958	-54,384 Reduced 94.83%	2,966 $4,000
Q2 2023 Aug 10, 2023	BUY	$1.79 - $2.9 $94,678 - $153,389	52,893 Added 1186.74%	57,350 $141,000
Q1 2023 May 11, 2023	SELL	$2.65 - $3.81 $2,957 - $4,251	-1,116 Reduced 20.03%	4,457 $13,000
Q4 2022 Feb 09, 2023	SELL	$3.38 - $4.22 $4,938 - $6,165	-1,461 Reduced 20.77%	5,573 $20,000
Q3 2022 Nov 10, 2022	SELL	$3.43 - $5.83 $29,950 - $50,907	-8,732 Reduced 55.39%	7,034 $25,000
Q2 2022 Aug 10, 2022	BUY	$4.41 - $5.69 $18,239 - $23,533	4,136 Added 35.56%	15,766 $83,000
Q1 2022 May 12, 2022	SELL	$4.81 - $6.99 $163,727 - $237,932	-34,039 Reduced 74.53%	11,630 $64,000
Q4 2021 Feb 10, 2022	BUY	$5.97 - $7.93 $138,456 - $183,912	23,192 Added 103.18%	45,669 $311,000
Q3 2021 Nov 10, 2021	BUY	$4.79 - $6.68 $107,664 - $150,146	22,477 New	22,477 $137,000

Others Institutions Holding CERS

# of Institutions

156

Shares Held

147M

Call Options Held

84.2K

Put Options Held

55.5K

View Full List

About CERUS CORP

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $317M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

More about CERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account